Thus, a better understanding of the cell-specific differences in the crosstalk between SG formation and NLRP3 activation is essential for developing promising targeted DDX3X drugs for the treatment of NASH. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.